SCHEMBL6095822

SCHEMBL6095822

CCOCCC(OCC)OC(=O)OC(C(C)C)n1nc(C(=O)OCC)c(C(=O)c2cc(OC)c(OC)cc2[N+](=O)[O-])n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.37
MAPT P10636 2/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 3/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
NPC1 O15118 1/20 0.36
CYP3A4 P08684 1/20 0.36
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
HTT P42858 1/20 0.35
GAA P10253 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MITF O75030 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TNF P01375 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095516 0.96 POLB (0.35) POLBMAPTTHRBLMNACASP3
SCHEMBL6093093 0.88 KDM4E (0.31) MAPT
SCHEMBL5509238 0.87 MAPT (0.41) POLBMAPTTHRBLMNACASP3
SCHEMBL5508693 0.87 MAPT (0.39) POLBMAPTTHRBLMNACASP3
SCHEMBL5510311 0.85 POLB (0.39) POLBMAPTTHRBLMNACASP3
SCHEMBL5515340 0.84 MAPT (0.40) POLBMAPTTHRBLMNACASP3
SCHEMBL6092816 0.84 MAPT (0.38) POLBMAPTLMNACYP3A4MEN1
SCHEMBL6095019 0.84 ALDH1A1 (0.33) MAPTALDH1A1
SCHEMBL5512020 0.84 MAPT (0.37) POLBMAPTTHRBLMNACASP3
SCHEMBL6093747 0.80 MAPT (0.39) POLBMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 POLB 2504/4885MAPT 3223/4885THRB 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.